bereum co.,ltd, a specialist in postbiotic, led by CEO Hwan Kwon Il, has signed an export and supply contract worth $980,000 for postbiotic pet food with Tecnocalidad of Colombia, under the leadership of CEO Harvey Ibanez Ortiz.Tecnocalidad is a subsidiary responsible for product imports of Agrocamp
On Jan. 19, Dong-A ST NeuroBo Pharmaceuticals announced the commencement of the global Phase 2 Part 2 clinical trial for its Metabolic dysfunction-associated steatohepatitis (MASH) treatment DA-1241.Last May, the company received approval from the U.S. Food and Drug Administration (FDA) for the glob
Celltrion Group has successfully sold the Asia-Pacific (APAC) “Primary Care” business rights, which it acquired from multinational pharmaceutical company Takeda Pharmaceuticals (hereafter Takeda) in 2020, after three years.On Jan. 18, Celltrion concluded a contract with Dong-A Pharmaceutical for the
Dong-A ST announced on Jan. 10 that it signed a business agreement with Eleven Therapeutics to develop RNA-based gene therapies. The agreement was finalized at the J.P. Morgan Healthcare Conference in San Francisco on Jan. 9.The collaboration will focus on discovering RNA therapies targeting fibroti
Dong-A ST announced on Jan. 4 that it has signed a license-in agreement with SK Biopharmaceuticals to license out its new epilepsy drug Cenobamate in 30 countries including Korea, Southeast and Southwest Asia, Russia, Australia, New Zealand, and Turkiye.Under the agreement, Dong-A ST will receive dr
Dong-A Socio Group’s specialty drug affiliate, Dong-A ST, will enter the ADC market through the acquisition of an antibody-drug conjugate (ADC) linker platform company. ADCs are a treatment that combines an antibody that combines a target antigen with a cytotoxic drug as a linker and is known for it
ST PHARM, a subsidiary of the Dong-A Socio Group, announced on Oct. 25 that its Oligo manufacturing facility, Banwol Campus, has successfully passed its regular Current Good Manufacturing Practices (cGMP) inspection conducted by the U.S. Food and Drug Administration (FDA). The company has also recei
GC Biopharma’s and SK plasma’s entries into Indonesia will accelerate this year. GC Biopharma is expected to finalize all procedures within this year after receiving approval for business rights related to the construction of a blood product factory and a technology transfer from the Indonesian gove
On April 20, Dong-A ST announced the results of a preclinical study of its immuno-oncology drug candidate “DA-4505” at the American Association for Cancer Research (AACR) 2023 held in Orlando, Florida in the United States from April 14 to 19.At this meeting, Dong-A ST presented the anti-tumor effect
NeuroBo Pharmaceuticals, a subsidiary of Dong-A ST, announced on April 4 that it has filed a second phase U.S. Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA) to develop DA-1241 for the treatment of non-alcoholic steatohepatitis (NASH).The clinical trial w
ST Pharm, a subsidiary of Dong-A Socio Group, announced on Feb. 23 that it signed an agreement with Multiverse Pharma in the United States for joint research on new antibody-encoding (AER) platform technology and biobetter mRNA drugs.Under the agreement, ST Pharm and Multiverse Pharma will develop f
The author is an analyst of KB Securities. He can be reached at joonsop.analyst@kbfg.com. -- Ed.Maintain BUY but lower target price We maintain BUY but cut our TP to KRW16,500 from KRW17,500 for LGU to reflect a change in COE (8.45%→9.12%). Our investment points include improved B2B earnings visibil
SsangYong Motor will be renamed KG Mobility and its new models will be launched under the KG brand, Kwak Jae-sun, chairman of KG Group, which has acquired the ailing automobile company, said.“We have decided to go for a new name to fully utilize the strength of SsangYong Motor,” said Kwak, who doubl
Dong-A ST announced on Nov. 9 that it has attracted US$32.3 million in investment from NeuroBo Pharmaceuticals under a technology licensing-out and equity investment deal with the U.S. company.In September, Dong-A ST transferred to NeuroBo its exclusive worldwide development and sales rights for DA-
Dong-A ST announced on Oct. 26 that it would purchase treasury stocks worth 10 billion won to enhance shareholder value.The stock repurchase plan will be implemented immediately beginning from Oct. 27. It will be carried out four times in a one-year period. The purchase method is a direct acquisitio
Hyundai Engineering and Construction (Hyundai E&C) has won a railway construction project in the Philippines, which is valued at US$1.33 billion.The company said on Sept. 18 that it has received a notice of award (NOA) for the construction of Sections 4, 5, and 6 of the Philippine Southern Urban Rai
Dong-A ST announced on Sept. 15 that it has signed a global license-out and equity investment contract with NeuroBo Pharmaceuticals of the United States on Sept. 14.Dong-A ST has licensed out DA-1241, a treatment for type 2 diabetes and nonalcoholic steatohepatitis, and DA-1726, a treatment for obes
Hanmi Pharmaceutical has obtained U.S. approval for its neutropenia treatment Rolontis, opening a new chapter in its R&D history. It is the first drug that Hanmi has succeeded in commercializing in the global market.Spectrum Pharmaceuticals, a U.S. partner to which Hanmi Pharmaceutical licensed out
Ildong Pharmaceutical announced on April 18 that it has established the Global Business Headquarters to strengthen its overseas business.The new organization will oversee the Overseas Business Development Department and the Drug Import and Export Department, and will be in charge of establishing a U
Dong-A ST, a prescription drug manufacturer affiliated with Dong-A Socio Group, has topped 1.3 trillion won in cumulative exports since 2011.The company announced on March 7 that it set a new export record of 140 billion won in 2021. Export growth was led by biopharmaceuticals. Sales of Eporon, a tr